A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
PHASE3
This study aims to compare the efficacy and safety of ICP-248 in combinatio...
Status
Not Yet Recruiting
Location
The First Affiliated Hospital of Anhui Medical University
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
PHASE1
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficac...